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Objective: To deﬁne for the ﬁrst time the transcriptomes of normal and end-stage osteoarthritis (OA) hip
cartilage.
Materials and methods: RNA was isolated from cartilage within 2 h of joint replacement surgery. Gene
expression was analyzed using Agilent GeneSpring GX 11 following hybridization to Illumina Human HT-
12 V3 microarrays. Real-time reverse-transcription polymerase chain reaction (RT-PCR) was used to
validate the expression of six genes identiﬁed by microarray as differentially expressed. Gene Set
Enrichment Analysis (GSEA) and Ingenuity Pathway Analysis (IPA) were used to investigate enriched
functions or canonical pathways amongst differentially expressed genes respectively.
Results: In total we identiﬁed 998 differentially expressed genes (fold change1.5, P-value 0.01)
between neck of femur fracture (NOF) (n¼ 10) and OA hip (n¼ 9) patient cartilage. These differentially
expressed genes were enriched within 71 canonical pathways. A comparison between a comparable knee
dataset20 only identiﬁed 229 genes similarly differentially expressed although remarkably 34 canonical
pathways overlapped between experiments.
Conclusions: This study is the ﬁrst to report a comprehensive gene expression analysis of human hip OA
cartilage compared to control (NOF) cartilage at the whole-genome level. Our differential gene expres-
sion dataset shows excellent correlation with similar deﬁned studies using comparable tissue but reveals
discord between hip and knee OA at the individual gene status but with commonality with regards the
molecular pathways involved.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is the most prevalent joint disease with the
typifying feature being the progressive degradation of articular
cartilage during disease progression. OA affects over 4 million
people in the UK with around 60% of those over the age of 60
showing signs of the disease1. Although loss of cartilage is charac-
teristic of OA, the disease also involves pathological changes to
ligaments, capsular tissue, periarticular muscle, nerve, subchondral
bone, meniscus and the synovium2,3. However, data show that OA
progression can be slowed by preventing cartilage degradation,D.A. Young, Musculoskeletal
or, Cookson Building, Medical
NE2 4HH, UK. Tel: 44-191-
s Research Society International. Pa mechanism presumably mediated by the only cell type of carti-
lage, the chondrocyte4. A detailed examination of the molecular
changes occurring in chondrocytes, and therefore cartilage, during
disease development is critical to further our understanding of OA.
Articular cartilage is composed predominately of an extracel-
lular matrix (ECM) containing proteoglycan (principally aggrecan)
and collagen (mainly type II). Turnover and remodeling of the
cartilage ECM is a normal physiological process mediated through
the regulation of the expression of matrix components and matrix-
degrading enzymes by the chondrocyte4. In OA the chondrocyte
phenotype alters, through as yet unidentiﬁed processes, such that
gene expression changes occur which mean the homeostatic
balance between anabolism and catabolism is lost in favor of the
latter. In terms of ECM catabolism, type II collagen is cleaved by
matrix metalloproteinases (MMPs), with MMP-13 the generally
accepted collagenase in OA. Pathological aggrecan cleavage is by ‘A
disintegrin and metalloproteinase with thrombospondin motifs’ublished by Elsevier Ltd. All rights reserved.
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from cartilage is reversible whilst collagen breakdown is not and
therefore represents an irreversible step in cartilage degradation6,7.
As well as alterations in the expression of many proteases8e10,
chondrocytes show altered expression of a number of pro-
inﬂammatory cytokines [e.g., Interleukin (IL)-1], cell receptors
(e.g., toll-like receptors), matrix proteins (type II and X collagens
and aggrecan) and several transcription factors11 which could
further exacerbate the degradative phenotype.
Since the chondrocyte appears central to OA pathogenesis
a complete knowledge of the genes differentially expressed in OA
and normal articular cartilage is required. To date, such compari-
sons are few and often limited in terms of using small data sets or
reliant on animal models12e17, although several studies have
examined gene expression changes between damaged and intact
cartilage within the same knee joint of OA patients13,16. One of the
ﬁrst studies to compare human normal vs OA cartilage identiﬁed
a decrease in expression of important oxidative defence genes
especially SOD2 and SOD318, a ﬁnding we recently veriﬁed19.
Although this initial study was limited due to the use of custom-
made cDNA arrays covering around only 4000 genes, a major
ﬁnding was that OA cartilage with no overt or only modest damage
had signiﬁcantly different gene expression proﬁles from healthy
tissue18.
The ﬁrst cartilage comparative study to use commercially
available microarrays compared gene expression changes within
ﬁve OA and ﬁve normal human knee patient cartilage biopsy
samples20. This identiﬁed 1423 genes as being signiﬁcantly differ-
entially expressed, many of which had not previously been asso-
ciated with OA such as COL8A2 and COL14A1. Considering the
differences of OA prevalence and severity between the sexes21 it
was somewhat surprising that with such a small mixed sex sample
size this study identiﬁed a large number of signiﬁcant changes. The
small sample size could have led to more false positives and, unlike
most high-throughput microarray experiments, the authors did not
apply multiple test correction when calculating signiﬁcant
P-values.
Herein, we used Illumina Human HT-12 V3 whole-genome
expression arrays to proﬁle the transcriptome of cartilage collected
from femoral heads of nine OA and ten neck of femur fracture (NOF)
patients, all of which were female. The aim of the study was to
investigate the molecular changes of chondrocytes in hip OA to
provide a comprehensive understanding of disease pathology via
identiﬁcation of the pathways involved. To our knowledge this is
the ﬁrst study to analyze gene expression changes in human hip OA
at the whole-genome level.
Materials and methods
Cartilage sample collection
Human articular cartilage samples were obtained from con-
sented patients undergoing joint replacement surgery due to either
end-stage hip OA or intracapsular NOF with Ethical Committee
approval from the Newcastle and North Tyneside Health Authority.
NOF fracture patients had no previous history of OA. Joints were
inspectedmacroscopically and scored using a scheme adapted from
Noyes classiﬁcation22 to include the presence of osteophytes
(Supplementary Table 1) by a blinded experienced orthopedic
surgeon. This adaptation to the Noyes classiﬁcation (which is
commonly used for arthroscopic knee cartilage scoring) was
necessary because there are currently no accepted classiﬁcations
for the macroscopic scoring of hip cartilage23. Hip samples scoring
1 were considered normal (control) while those scoring 5 were
classiﬁed as osteoarthritic. For all joints macroscopically normalcartilage was collected, in the OA patients avoiding areas of obvious
ﬁbrillation, snap frozen in liquid nitrogenwithin 2 h of surgery and
stored at 80C prior to RNA extraction. All cartilage was washed
extensively in phosphate buffered saline (PBS) to avoid
contamination.
RNA extraction
Cartilage samples were ground into powder and homogenized
using Invitrogen TRIzol Reagent (Life Technologies, Paisley, UK)
prior to RNA puriﬁcation using the Qiagen RNeasy mini kit (Qia-
gen, Crawley, UK) essentially as previously described9. Quantity and
quality of RNA samples were measured with a NanoDrop spectro-
photometer (Thermo Fisher Scientiﬁc, MA, USA) and RNA integrity
checked using an Agilent Bioanalyzer 2100 (Agilent Technologies,
Santa Clara, CA, USA). RNA samples with RNA Integrity Number
(RIN) 7 were selected for whole-genome expression array
experiments.
Gene expression proﬁling and analysis
Illumina whole-genome expression array Human HT-12 V3
(Illumina Inc., Illumina United Kingdom, Saffron Walden, UK) was
used to proﬁle gene expression of RNA samples according to the
manufacturer’s protocol. Raw expression data were analyzed using
Agilent GeneSpring GX 11 (Agilent Technologies, Santa Clara, CA,
USA). Raw data were normalized with a quantile algorithm24 and
the baseline was transformed to the median of all samples. Those
probes with a ﬂag value of ‘Present’ or ‘Marginal’ in 80% of either
OA or NOF samples were selected for further analysis. R package
Combat was used to adjust the data to remove any possible batch
effect incurred during RNA preparation25,26.
Functional and pathway analysis of differentially expressed genes
Gene Set Enrichment Analysis (GSEA) was used to investigate
enriched functions of differentially expressed genes27. The differ-
entially expressed gene list was ranked according to their fold
changes and compared with sets of genes that were classiﬁed
according to the gene ontologies for molecular function, cellular
component and biological process28. Results with P-value 0.05
and false discovery rate (FDR)0.25 were considered as signiﬁcant.
Ingenuity Pathway Analysis (IPA) (Ingenuity Systems, www.
ingenuity.com) was used to identify canonical pathways associ-
ated with the differentially expressed genes. All of the differentially
expressed genes were included in the analysis. P-values 0.05
were used to ﬁlter results.
Protein interaction network analysis
Protein interactions among up- and down-regulated genes in OA
samples were analyzed with the use of the search tool STRING29. We
used STRING with three data sources (‘genomic context’, ‘high-
throughput experiments’ and ‘co-expression’) to detect and predict
interactions between proteins. We did not include the data source
‘previous knowledge’ to derive results since these are data taken from
text-mining and is therefore not determined experimentally. A gene
withﬁve interactions with other genes was classiﬁed as a hub.
Real-time reverse-transcription polymerase chain reaction (RT-PCR)
To verify the microarray results, RNA (0.5 mg) from OA and NOF
cartilage was reverse transcribed into cDNA using M-MLV reverse
transcriptase (Life Technologies, Paisley, UK) as previously
described30 and gene expression determined using TaqMan Gene
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COL2A1, CTSK, NOD2/NLRC2, SOD2 and 18S as a housekeeping gene.
Real-time RT-PCR was performed using TaqMan Gene Expression
mastermix (Life Technologies) with the ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems, Foster City, CA,
USA) according to the manufacturer’s protocol and as previously
reported31. Target gene expression was normalized to 18S expres-
sion levels using the calculation 2DCt.
Statistical analysis
From the microarray analysis signiﬁcance of differentially
expressed genes was evaluated with a ManneWhitney U test,
which is nonparametric, and corrected for multiple testing using
the BenjaminieHochberg32 method. Differentially expressed genes
with a fold change  1.5 and P-value 0.01 were included in
further analyses. Statistical analysis of differential expression
between OA and NOF cartilage samples using real-time RT-PCR data
also used the ManneWhitney U test where P-values< 0.05 (*) were
considered signiﬁcant. GSEA uses a permutation test procedure to
evaluate the signiﬁcance of gene ontology (GO) term
enrichments. Because these P-values are not multiple testing
corrected, a FDR (calculated as described27) of 0.25 was used as
threshold to control the number of false positives. The Fisher’s
exact test, implemented in IPA (Ingenuity Systems, www.ingenuity.
com) and other pathway analysis applications33, was used to assess
the signiﬁcance of the association between a pathway and the
differentially expressed genes. The Pearson product-moment
correlation coefﬁcient was used to test the correlation of fold
changes of overlap genes between the Karlsson20 and our study.
Results
Cartilage sample collection
In total 19 cartilage samples were collected from femoral heads
of female OA donors (nine samples; median age¼ 72 years), and
female NOF donors (ten samples; median age¼ 76 years). All
donors were UK citizens of North European descent. The OA
cartilage samples had obvious OA signs including degraded and
ﬁbrous cartilage with osteophytes and exposed subchondral bone.
Compared to OA joints, the NOF femoral heads had fully intact
cartilage with little ﬁbrillation and no exposed bone (Fig. 1A and B
respectively). Macroscopic scoring, using an adaptation of the
Noyes classiﬁcation22, conﬁrmed the two sample groups were
signiﬁcantly different (P 0.001) with OA samples having a mean
score of 5.2 and NOF 0.6 (Supplementary Table 1 and Fig. 1C).
Followingmicroarray analysis, unsupervised hierarchical clustering
of cartilage samples based on expression of all genes passing the
quality ﬁlter showed perfect segregation of the OA and NOF
samples (Fig. 1D).
Differentially expressed genes and functional analysis
In total we identiﬁed 998 differentially expressed genes (fold
change1.5 or  þ1.5, P-value 0.01) between the two sample
groups (shown in Supplementary Table 2). These included 465 up-
regulated and 533 down-regulated genes. Amongst these, 351
genes showed a two-fold change of expression level. A number of
these genes have previously been shown to be differentially
expressed between hip OA and NOF cartilage including ADAMTS1,
ADAMTS5, ADAMTS9, MMP1, MMP3, MMP23 and SOD28e10,19
consistent with the data herein. The most robust down-
regulation was observed for chemokine ligand 20 (CCL20) which
showed >22-fold less expression in the OA group. Within the mostup-regulated genes are a number of collagen genes; COL2A1,
COL5A2, COL9A1 and COL11A1, all of which have previously been
reported to be up-regulated in OA cartilage18.
The predominant functions of up- and down-regulated genes
within the three GO categories (molecular function, cellular
component and biological process) were assessed (Table I; the genes
contributing to each enriched term are listed in Supplementary
Table 3). In terms of ‘molecular function’, the results indicate
increased receptor activity and decreased oxidoreductase activity in
OA cartilage. With regards to ‘cellular components’, ECM was
enriched in the down-regulated gene lists. Although both up- and
down-regulated genes lists contain approximately equal numbers of
genes, those with reduced expression were classiﬁed into a far
greater diversity of biological processes, such as stress responses, cell
death and cellular processes. Of the up-regulated gene list within
‘biological processes’ all featured aspects of development,with in fact
‘negative regulationof development’ enriched in thedown-regulated
gene list.
Molecular pathway and protein interaction network analysis
The entire list of differentially expressed genes was found to be
signiﬁcantly (P 0.05) associated with 71 canonical pathways
(Table II), a number of which have previously been associated with
OA34e38. Interestingly, the pathway analysis identiﬁed a possible
role for IL-17 signaling in OA, generally based upon the altered
expression of AKT3, IL8, mitogen-activated protein kinase (MAPK)1,
MAPK10 and NFKB2. In all, six cancer signaling pathways showed
a signiﬁcant over-representation within the dataset. Within these
cancer pathways a total of 58 genes were differentially expressed,
with altered AKT3, CDKN1A, FZD2, FZD4, FZD7, FZD9, MAPK1,
MAPK10,MYC, PDGFC and SMO expression providing a common link
between the majority of these pathways.
Network analysis was performed on all genes either up- or
down-regulated in the OA tissue using STRING29. In total, nine up-
and 11 down-regulated genes were assigned as hubs (ﬁve inter-
actions) (Table III). All these hubs were concentrated to four
networks with a large network of 65 genes identiﬁed for the down-
regulated genes (Fig. 2).
Real-time RT-PCR veriﬁcation
Real-time RT-PCR was used to validate the expression levels of
six genes identiﬁed as differentially expressed by the microarray
study, three down-regulated (SOD2, NOD2/NLRC2 and CDKN1A) and
three up-regulated (CAMK2G, COL2A1 and CTSK). After normaliza-
tion to 18S expression all six genes were conﬁrmed as signiﬁcantly
differentially expressed by both techniques with expression
changes always in the predicted direction (Table IV).
Comparison of knee vs hip OA gene expression
This is the ﬁrst study to comprehensively investigate gene
expression changes of hip OA cartilage. However, a similar study
using knee OA vs normal cartilage has been reported20. In total,
1423 genes (1418 different genes including ﬁve duplicates)
showed differential expression in the knee study, of which only
229 genes were also differentially expressed here (Fig. 3A and
Supplementary Table 4). In fact, of these overlapping genes, only
158 (11% of the 1418) showed regulation in the same direction
although there was a signiﬁcant positive correlation for such
a trend (Fig. 3B and C). Genes that increased in both tissues with
disease included a large number of collagens, including COL2A1,
COL5A1, COL5A2, COL8A2, COL11A1, and COL13A1. Remarkably,
given the small gene overlap, pathway analysis showed that 34
Fig. 1. OA and NOF femoral heads and clustering. (A), A typical OA femoral head with exposed bone (black arrow) and ﬁbro-cartilage (white arrow). Macroscopically normal
cartilage can be observed (*) which was collected and processed as described. (B), A typical NOF femoral head with a covering of smooth healthy cartilage. (C), A sample of blinded
cartilage phenotype scores based on the Noyes classiﬁcation22. Circles OA, squares, NOF. Line mean, error bars are standard error of the mean, ***represents P< 0.001. (D),
Unsupervised hierarchical clustering of cartilage samples based on microarray expression proﬁles. Distances between samples were measured with Euclidean algorithm and
clustered with the Complete-linkage method. The NOF and OA samples are contained in two separated clusters consistent with both diagnosis and the blinded cartilage OA scores (C
and Supplementary Table 1). Differentially expressed genes are provided in Supplementary Table 2.
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(P 0.05) are also associated with knee OA (Fig. 3D and
Supplementary Table 5). Of these, ‘Role of Macrophages, Fibro-
blasts and Endothelial Cells in Rheumatoid Arthritis’ and ‘Role of
Osteoblasts, Osteoclasts and Chondrocytes in Rheumatoid
Arthritis’ contained the largest number of overlapping differen-
tially expressed genes. The ‘Oncostatin M Signaling’ pathway
contained the highest ratio of differentially expressed genes
(around 21% of all genes within that pathway).
Discussion
To our knowledge this is the ﬁrst report to comprehensively
relate gene expression changes in humans between normal (NOF)
and OA hip cartilage at the whole-genome level. Several studies
have compared gene changes using similar samples via a real-time
RT-PCR technique but have generally focussed on speciﬁc genes,
originally metalloproteinase family members8,9, and more
recently the entire degradome10. Although the datasets are
different, reﬂecting the differences in techniques, all the proteases
expressed differentially in both screens followed identicalexpression patterns in terms of direction (up- or down-
regulation), thus validating our samples and the microarray
approach that we have taken here. We also conﬁrmed the differ-
ential expression of six genes (three up- and three down-
regulated) from our microarray data using real-time RT-PCR,
further validating the microarray platform.
In total we found 998 genes differentially expressed with a fold
change 1.5, in line with the only other whole-genome human
cartilage study20. However, we found an almost equal number of
genes were increased and decreased in the disease unlike the
previous study which reported more genes with an increase in
expression in knee OA cartilage20. Using functional enrichment
analysis ‘receptor activity’ appeared up-regulated in OA. ‘Oxidore-
ductase activity’ was signiﬁcantly down-regulated which is in
keeping with a previous report that found a down-regulation of
oxidative damage defence genes, including SOD2 and SOD3, in OA
cartilage18, a ﬁnding we recently validated19. A decrease in oxida-
tive defence/reductase activity would lead to an increase in reactive
oxygen species and oxidative stress, a process that has been
demonstrated in OA and shown to negatively affect chondrocyte
function39.
Table I
Functions enrichment analysis result. Enriched functions of up- and down-regulated genes are listed in the table and separated into three GO term categories. Down-regulated
genes associate with a large number of functions
Name Number of genes P-value FDR
Molecular functions e up-regulated genes
Receptor activity 19 0.03252 0.16421
Molecular functions e down-regulated genes
Oxidoreductase activity 12 0.00322 0.101251
Cellular components e up-regulated genes
Cytoskeleton 17 0.02222 0.173645
Cellular components e down-regulated genes
Extracellular space 12 <0.001 0.00291
Extracellular region 15 0.00462 0.031634
Extracellular region part 14 0.00306 0.033787
Cell fraction 20 0.0354 0.11638
Cytosol 16 0.04186 0.148141
Biological process e up-regulated genes
Skeletal development 14 <0.001 <0.001
System development 41 <0.001 <0.001
Multicellular organismal development 51 <0.001 0.00128
Organ development 30 <0.001 <0.001
Anatomical structure development 42 <0.001 0.00282
Tissue development 8 0.03608 0.064441
Biological process e down-regulated genes
Response to stress 35 <0.001 <0.001
Response to external stimulus 18 <0.001 <0.001
Immune system process 12 <0.001 0.002074
Cellecell signaling 8 <0.001 0.003765
Response to chemical stimulus 15 <0.001 0.004706
Regulation of biological quality 18 <0.001 0.005458
Cell development 33 <0.001 0.008281
Negative regulation of biological process 44 <0.001 0.015126
Negative regulation of cellular process 43 0.00137 0.016361
Positive regulation of biological process 35 0.00145 0.046702
Apoptosis GO 29 0.00154 0.048721
Biopolymer metabolic process 86 0.00244 0.055773
Programmed cell death 29 0.0074 0.046237
Nucleobase nucleoside nucleotide and
nucleic acid metabolic process
63 0.01023 0.089193
Negative regulation of programmed cell death 13 0.01136 0.075655
Negative regulation of apoptosis 13 0.01311 0.07687
Signal transduction 50 0.01573 0.092226
Negative regulation of developmental process 13 0.01681 0.071763
Transcription 41 0.02225 0.087059
Post translational protein modiﬁcation 39 0.02252 0.09556
Transcription DNA dependent 38 0.02453 0.094392
Regulation of signal transduction 10 0.0264 0.094384
Positive regulation of cellular process 31 0.02643 0.088213
Regulation of programmed cell death 21 0.02786 0.068843
RNA biosynthetic process 38 0.02813 0.090182
Cellular macromolecule metabolic process 53 0.03369 0.116554
Regulation of apoptosis 21 0.034 0.071935
Regulation of cellular metabolic process 39 0.03411 0.105437
Cellular protein metabolic process 53 0.03811 0.113504
Regulation of metabolic process 41 0.03894 0.097848
Regulation of cell proliferation 17 0.039 0.089349
RNA metabolic process 48 0.04049 0.112741
Biopolymer modiﬁcation 33 0.04545 0.111759
Regulation of gene expression 35 0.04909 0.115718
Transcription from RNA polymerase II promoter 32 0.04944 0.115356
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upon IL-17 or cancer signaling. Common to many of these were
MAPK1 and AKT3. In fact these factors were also present in several
other highlighted pathways and are pivotal components of phos-
phatidylinositol 3-kinase (PI3K)/Akt-signaling. We recently found
that inhibition of Akt-signaling was chondroprotective and that
depletion of AKT3, which is a serine/threonine kinase, in primary
human articular chondrocytes reduced pro-inﬂammatory cytokine
mediated induction ofMMP-13, but notMMP-140. In our screenAKT3
has reducedexpression inOA, suggestiveof anattempt toprotect the
remaining cartilage from further metalloproteinase-mediated
destruction. The CC-chemokine, CCL20 (also known as MIP-3a)
was the most down-regulated gene identiﬁed from our array andalso appears to be an important target for IL-17 signaling41. CCL20
bindsmonogamously to the receptor CCR6 and interestingly signals
via the Akt and/or ERKMAP Kinase pathway (see below). CCL20 acts
as a chemoattractant for CCR6-expressing cells such as dendritic
cells. There has been little research on CCL20 inOA pathogenesis but
it has been suggested that it contributes to ECM-bone remodeling42.
However, in rheumatoid arthritis (RA), CCL20 produced by synovial
cells is thought to play a pivotal role in the recruitment of arthrito-
genic Th17 (CD4þ T cells that secrete IL-17A) cells to the inﬂamed
joint43.
MAPK1 (ERK2) and MYC (c-Myc) were also genes with the most
STRING connections from our study, partly reﬂecting the volume of
research around these factors. The ERK MAP kinase pathway has
Table II
Associated pathways of the differentially expressed genes. Sixty pathways in total
were identiﬁed as associated with the differentially expressed genes. Several of
these (bold) have been previously reported as associated with OA34e38. Seven
pathways are related with IL-17 signaling. The ratio column is the proportion of
differentially expressed genes divided by the total number of genes associated with
a pathway
Ingenuity canonical pathways P-value Ratio
Colorectal cancer metastasis signaling <0.0001 0.12
IL-17A signaling in ﬁbroblasts <0.0001 0.26
Glioblastoma multiforme signaling <0.0001 0.13
ILK signaling <0.0001 0.12
Role of macrophages, ﬁbroblasts
and endothelial cells in RA
<0.0001 0.09
Role of osteoblasts, osteoclasts and
chondrocytes in RA
<0.0001 0.11
Basal cell carcinoma signaling 0.0001 0.17
Glycosaminoglycan degradation 0.0001 0.26
TREM-1 signaling 0.0001 0.18
IL-17 signaling 0.0001 0.16
Molecular mechanisms of cancer 0.0001 0.09
Wnt/b-catenin signaling 0.0004 0.11
Ovarian cancer signaling 0.0004 0.12
Role of IL-17F in allergic
inﬂammatory airway diseases
0.0005 0.18
Aryl hydrocarbon receptor signaling 0.0006 0.11
Role of NANOG in mammalian
embryonic stem cell pluripotency
0.0007 0.12
Factors promoting cardiogenesis
in vertebrates
0.0009 0.13
Human embryonic stem cell pluripotency 0.0009 0.10
Role of IL-17A in arthritis 0.0010 0.15
Oncostatin M signaling 0.0010 0.21
Pancreatic adenocarcinoma signaling 0.0015 0.11
p53 signaling 0.0016 0.13
Arginine and proline metabolism 0.0017 0.14
Production of nitric oxide and reactive
oxygen species in macrophages
0.0021 0.10
Role of Wnt/GSK-3b signaling in the
pathogenesis of inﬂuenza
0.0024 0.12
O-glycan biosynthesis 0.0026 0.19
Bladder cancer signaling 0.0029 0.12
IL-17A signaling in airway cells 0.0030 0.13
PI3K/AKT-signaling 0.0032 0.10
HIF1a signaling 0.0032 0.11
PTEN signaling 0.0041 0.10
Inhibition of angiogenesis
by TSP1
0.0044 0.18
Corticotropin releasing
hormone signaling
0.0055 0.10
Ascorbate and aldarate metabolism 0.0060 0.21
IL-8 signaling 0.0076 0.09
Amyloid processing 0.0083 0.13
Dendritic cell maturation 0.0087 0.08
Phospholipase C signaling 0.0091 0.08
IL-12 signaling and production
in macrophages
0.0095 0.09
Protein kinase A signaling 0.0107 0.08
p38 MAPK signaling 0.0110 0.10
Prostate cancer signaling 0.0129 0.10
Circadian rhythm signaling 0.0151 0.15
Interferon signaling 0.0170 0.15
NF-kB signaling 0.0186 0.08
Caveolar-mediated endocytosis
signaling
0.0200 0.10
HGF signaling 0.0200 0.10
Axonal guidance signaling 0.0204 0.07
Role of NFAT in regulation of the
immune response
0.0214 0.07
Role of IL-17A in psoriasis 0.0219 0.23
Atherosclerosis signaling 0.0219 0.09
LXR/RXR activation 0.0234 0.09
CCR5 signaling in macrophages 0.0282 0.08
Hypoxia signaling in the
cardiovascular system
0.0282 0.10
Insulin receptor signaling 0.0288 0.08
IL-17A signaling in gastric cells 0.0295 0.16
Table II (continued )
Ingenuity canonical pathways P-value Ratio
Role of JAK family kinases in
IL-6-type cytokine signaling
0.0295 0.15
HMGB1 signaling 0.0316 0.09
Thrombin signaling 0.0324 0.08
VDR/RXR activation 0.0324 0.10
Semaphorin signaling in neurons 0.0339 0.12
Reelin signaling in neurons 0.0347 0.10
Glioma signaling 0.0363 0.08
Sphingosine-1-phosphate signaling 0.0380 0.08
IL-15 production 0.0380 0.13
Sertoli cellesertoli cell junction signaling 0.0398 0.07
Aminosugars metabolism 0.0407 0.10
MIF regulation of innate immunity 0.0407 0.11
Breast cancer regulation by stathmin1 0.0447 0.07
Sonic hedgehog signaling 0.0479 0.13
Role of NFAT in cardiac hypertrophy 0.0490 0.07
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loproteinase gene expression31. Recently, ERK1/2 signaling was
found to be involved in the regulation of hypertrophic changes of
normal articular cartilage chondrocytes induced by osteoarthritic
subchondral osteoblasts44. MYC expression in OA cartilage corre-
lates with apoptosis of the chondrocytes45. ATF3 (activating tran-
scription factor 3) also featured strongly in both our IPA and STRING
analyses. ATF3 is a transcription factor induced by various stress
signals and proposed to be a hub of the cellular adaptive-response
network46. ATF3 down-regulation adds support to the hypothesis
that OA chondrocytes becomes less responsive to stimuli47. Pain in
OA is complex and poorly understood, but recently ATF3 has been
used as a marker of nerve injury in lumbar (L)4 and L5 dorsal root
ganglia of the ipsilateral knee in a rat knee OA model48. Both
GADD45a and GADD45b also featured in the down-regulation
STRING analysis with both having been previously identiﬁed as
down-regulated in OA cartilage as part of a microarray analysis.
GADD45b has been proposed to play a role in chondrocyte
homeostasis via the regulation of collagen gene expression and the
promotion of cell survival17.
Herein we also compared gene expression differences between
hip and knee OA, providing lists of genes and molecular pathways
common to both disorders. Common between the two tissues wasTable III
Differentially expressed genes that have more than ﬁve interactions with other
differentially expressed genes, listed for up- and down-regulated genes separately
Up-regulated genes No. of connections
COL11A1 8
COL2A1 6
COL5A1 6
COL5A2 6
ITGA11 6
ITGB7 6
GNG2 5
SDC1 5
SDC2 5
Down-regulated genes No. of connections
MYC 15
MAPK1 10
AK2 6
EPAS1 6
JAK2 6
ADK 5
AKT3 5
AMPD3 5
ATF3 5
ITGA1 5
NT5C3 5
Fig. 2. Protein interaction network of genes. Network analysis was performed on all genes either up- or down-regulated in the OA tissue using STRING29. (A and B) Interaction
networks of up-regulated genes. (C and D) Interaction networks of down-regulated genes. Hub genes, which have ﬁve connections, are highlighted in red.
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collagens, purportedly as an ineffectual repair response49. Similar
increases in matrix genes with OA have been reported by others18.
Importantly, this work also highlights gene differences between OA
in both tissues. A clear difference in the hip and knee datasets is
present when examining the expression of metalloproteinases. The
expression of the collagenase gene MMP-1 and the aggrecanase
gene ADAMTS-5, along with ADAMTS1, were all increased in knee
OA cartilage but decreased in hip OA cartilage, an observation that
has been reproducibly observed8e10. This could suggest the disease
mechanisms are fundamentally different, reﬂect the stage of
disease at which hip or knee replacement surgery occurs, or be due
to the normal comparator group, healthy tissue20 or NOF fracture
herein. In a preliminary study, gene expressionwithin NOF fracture
or post-mortem was largely similar, validating the use of NOF as
a control tissue9. The OA femoral tissue used within this study was
end-stage disease with signiﬁcant cartilage damage, as exempliﬁed
by the high score using the modiﬁed Noyes system22. However, we
only examined gene expression inmacroscopically normal cartilage
taken from the OA patients, yet signiﬁcant gene expression differ-
ences were observed between this cartilage and the NOF control
tissue. This ﬁnding supports the concept that even OA cartilage
tissue of healthy macroscopic appearance is not necessarily free ofTable IV
Real-time RT-PCR validation of six genes identiﬁed by the microarray analysis as
signiﬁcantly differentially expressed between OA and NOF hip cartilage. Real-time
RT-PCR expression was normalized to 18S expression
Gene Real-time RT-PCR Microarray
P-value Fold change P-value Fold change
CAMK2G 0.0008 2.0 0.0056 1.5
CDKN1A 0.0001 3.5 0.0056 6.4
COL2A1 <0.0001 10.0 0.0056 4.5
CTSK <0.0001 2.1 0.0056 1.9
NOD2 0.0003 6.9 0.0056 4.5
SOD2 <0.0001 35.1 0.0056 14.7disease18. The OA tissue used was taken from patients undergoing
joint replacement surgery therefore the gene expression hereinwill
likely be distinct from those occurring at initiation or during
disease progression. The relatively small number of overlapping
differentially expressed genes between our hip and the knee OA
studies may reﬂect a difference in the tissues or the analysis
undertaken50. However, even taking this into consideration,
a remarkable number of pathways appeared to be conserved
features of the disease in both tissues. These included ‘Role of
Macrophages, Fibroblasts and Endothelial Cells in Rheumatoid
Arthritis’ and ‘Role of Osteoblasts, Osteoclasts and Chondrocytes in
Rheumatoid Arthritis’ perhaps unsurprisingly given their link to
arthritis, and Wnt/b-catenin, IL-8 and IL-17 Signaling. However,
‘Oncostatin M Signaling’ contained the highest proportion of
differentially expressed genes within a given pathway (approxi-
mately 21%). Oncostatin M in combination with other pro-
inﬂammatory cytokines has been extensively linked to the induc-
tion of metalloproteinases by chondrocytes51. ‘triggering receptor
expressed on myeloid cells (TREM)1 signaling’ also contained
a high proportion of differentially expressed genes from both tissue
gene lists. TREM proteins are a family of cell surface receptors that
participate in diverse cell processes including inﬂammation, where
they act in concert with other receptors to amplify an inﬂammatory
response, and bone homeostasis where they play a role in osteo-
clastogenesis52. The role of TREM signaling in chondrocytes and
cartilage remains to be determined, though TREM-1 is up-regulated
in RA synovium53 and is proposed as a new therapeutic target in
the disease54. A number of pathways associate only with hip OA
cartilage including pathways connected with proteoglycans
‘Glycosaminoglycan Degradation’ and ‘O-Glycan Biosynthesis’ and
more novel pathways such as ‘Circadian Rhythm Signaling’. Knee
OA speciﬁc pathways included ‘IGF-1 Signaling’ and ‘Ephrin
Signaling’, both of which have established links with the disease or
chondrocytes55,56.
In conclusion, to our knowledge this is the ﬁrst study to compare
gene expression changes in osteoarthritic femoral hip cartilage to
that of patients with no signs of OA at the whole-genome level.
Fig. 3. A comparison of the differentially expressed genes identiﬁed in hip and knee OA20 compared to their respective normal cartilage. (A), Size-dependent Venn diagram of the
differentially expressed gene lists identiﬁed from our hip and the published knee20 studies. Only 229 genes were identiﬁed as differentially expressed in common between both
studies. (B), Four-way Venn diagram of hip and knee differentially expressed genes including direction of expression change. DW, down-regulated; UP, up-regulated. (C), Scatter plot
of fold changes of the overlapped genes. X-axis represents the fold change result of the genes in this study (hip) and Y-axis the knee OA study20. Green points indicate genes that are
signiﬁcantly differentially expressed in the same direction (up- or down-regulated in OA) in both studies. Red points indicate genes that are regulated in the opposite direction. N,
number of genes in each quadrant. Despite the large discrepancy in differentially expressed genes, the fold changes of these overlapping genes are signiﬁcantly co-related. (D), Size-
dependent Venn diagram of the pathways identiﬁed as associated with the differentially expressed knee and hip OA gene lists. Approximately half of the pathways associated with
our differentially expressed gene list for hip were also identiﬁed in the knee OA study indicating that, although the gene lists are largely different between joints, many of the same
pathways are involved in OA.
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17 signaling along with a number of genes that appear integral to
signaling, including CCL20 and MAPK1, and subsequent responses,
such as ATF3, all of which may have a role in OA pathogenesis.
Importantly, by comparing gene expression changes between hip
and knee OA both commonality, such as the ‘TREM1 signaling
pathways’, and discord such as the ‘O-Glycan Biosynthesis’ in hip
and ‘IGF-1 signaling’ in knee OA are observed. Although proteolytic
loss of cartilage typiﬁes OA57 in both hip and knee joints, our
observations add to the notion that the molecular mechanisms
underpinning such destruction may have some unique and speciﬁc
differences. Exploitation of thesemay proffer the potential formore
tailored, joint-speciﬁc therapies that circumvent the negative
aspects associated with direct metalloproteinase inhibition57.
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